echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Haematol: Targeted capture sequencing for genomic analysis of multiple myeloma

    Br J Haematol: Targeted capture sequencing for genomic analysis of multiple myeloma

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Previous genomic studies have revealed the genome map of myeloma cells.


    The researchers analyzed 154 newly diagnosed multiple myeloma patients.


    diagnosis

    In summary, this study provides detailed information about genomic abnormalities, which may have potential clinical applications for patients with multiple myeloma.


     

    Original source:

     

    Takashi Kanamori, et al.


    ncbi.
    nlm.
    nih.
    gov/32386081/" target="_blank" rel="noopener">Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.